Pyrrolobenzimidazolones and their use as antiproliferative agents
申请人:Boehringer Ingelheim International GmbH
公开号:EP1598353A1
公开(公告)日:2005-11-23
The invention relates to pyrrolobenzimidazolone compounds of formula (I),
wherein A,T and R1 to R3 are defined as in claim 1, which possess tubulin inhibitory activity and are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.
This invention relates to selenophene compounds of formula (I) shown below:
Each variable in formula (I) is defined in the specification. These compounds can be used to treat cancer.
[EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DES PROTÉINES KINASES
申请人:DCB USA LLC
公开号:WO2009085040A1
公开(公告)日:2009-07-09
This invention relates to selenophene compounds of formula (I) shown below; each variable in formula (I) is defined in the specification. These compounds can be used to treat cancer.
Nonstabilized Azomethine Ylides in the Mannich Reaction: Synthesis of 3,3-Disubstituted Pyrrolidines, Including Oxindole Alkaloids
作者:Evgeny M. Buev、Vladimir S. Moshkin、Vyacheslav Y. Sosnovskikh
DOI:10.1021/acs.joc.7b02193
日期:2017.12.1
situ generated nonstabilized azomethine ylides via the domino Mannich reaction–dipolar cycloaddition to form 3,3-disubstituted pyrrolidines, including oxindole alkaloids. When the starting material possesses a single activated hydrogen, the reaction terminates at the Mannich base stage. The developed methodology was applied to a short and efficientsynthesis of (±)-horsfiline and N-protected (±)-coerulescine
Pyrrolobenzimidazolones and their use as anti-proliferative agents
申请人:McConnel Darryl
公开号:US20050261350A1
公开(公告)日:2005-11-24
The invention relates to pyrrolobenzimidazolone compounds of formula (I),
wherein A, T and R
1
to R
3
are defined as in claim
1,
which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.